Related Experiment Videos
Primary chemotherapy for stage 2 testis cancer
R P Abratt1, G L McAdam, A R Pontin
1Department of Radiation Oncology, Groote Schuur Hospital.
Summary
Primary chemotherapy is effective for stage 2 testis cancer, including non-seminomatous germ cell tumors and bulky seminomas. This treatment offers high survival rates with manageable toxicity, establishing it as the preferred approach.
Area of Science:
- Oncology
- Urology
- Medical Oncology
Background:
- Testis cancer, specifically stage 2 with retroperitoneal lymph node metastases, requires effective treatment strategies.
- Assessing the efficacy and toxicity of primary chemotherapy is crucial for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of primary chemotherapy in patients with stage 2 testis cancer.
- To determine the optimal treatment approach for different subtypes of stage 2 testis cancer.
Main Methods:
- Retrospective review of 20 consecutive patients with stage 2 testis cancer treated between September 1992 and March 1994.
- Treatment involved 4 cycles of cisplatin, etoposide, and bleomycin, followed by retroperitoneal lymph node dissection (RPLND) or irradiation for residual masses.
Main Results:
- Complete response to chemotherapy was achieved in 70% of non-bulky non-seminomatous germ cell tumour (NSGCT) patients, with 100% survival.
- Bulky NSGCT showed no complete response to chemotherapy, with a 52% survival rate.
- Bulky seminoma patients had a 100% survival rate.
- Toxicity was generally modest, with one postoperative death.
Conclusions:
- Primary chemotherapy is the treatment of choice for stage 2 testis cancer.
- The regimen demonstrated high efficacy and acceptable toxicity for both NSGCT and seminoma subtypes.
- Successful fertility preservation was noted in four patients post-treatment.